Cabaletta Bio, Inc. (CABA)

Cabaletta Bio's stock has experienced notable movements in the past six months. The share price was $4.00 as of May 7, 2026, a substantial increase from $1.21 on May 8, 2025. Shares jumped 30% in May 2026 after the company reported promising early data from patients with pemphigus vulgaris treated with rese-cel. Cabaletta Bio launched an underwritten public offering of 51,725,000 shares at $2.90 per share, aiming to raise approximately $150 million. Insider buying activity has also been observed.

Based on available information, there is not enough data to identify clear demand seasonality for Cabaletta Bio, Inc.'s products and services. Demand would primarily be driven by clinical trial progress, regulatory approvals, and the prevalence of the targeted diseases.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company operates in the Healthcare sector, specifically in the Biotechnology industry. Cabaletta Bio's core approach is the CABA™ platform, which employs two complementary strategies: CARTA and CAART. The lead product candidate from the CARTA strategy is rese-cel, which is being evaluated in the RESET™ clinical development program across multiple therapeutic areas. The CAART strategy includes clinical-stage candidates such as DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. Another product in their pipeline is FVIII-CAART.

Cabaletta Bio, Inc.'s headquarters and laboratories are located in Philadelphia, Pennsylvania. The company has established a significant clinical footprint across the United States for its rese-cel program.

Cabaletta Bio's brand reputation has been positively influenced by several key events and developments in the past year. The company has generated exciting efficacy data in lupus and myositis trials. Advancements in manufacturing are expected to lower the cost of goods sold and enhance efficiency. The FDA's granting of a Regenerative Medicine Advanced Therapy (RMAT) designation to rese-cel for systemic sclerosis further bolsters the company's standing. Cabaletta Bio actively participates in various healthcare conferences, presenting clinical and translational data.

The ownership structure of Cabaletta Bio is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion, ranging from approximately 14.20% to 55% of the company's stock. Major institutional owners include T. Rowe Price Investment Management, Inc., Bain Capital Life Sciences Investors, LLC, and others. Insiders own approximately 1.52% of the stock, while the general public and individual investors hold a substantial share, estimated between 19% and 79.12%. Recent insider trading activity shows purchases by the President & CEO, Chief Commercial Officer, Chief Medical Officer, and other executives.